WHAT IS CLAIMED IS:

. **}**~

1. A compound represented by formula (1):

A-X-Q-(CH₂)n R1 R3 R1 R3 R2 R2

or heterocyclic group which has 1 to 4 substituents selected from the group consisting of a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, an alkyl group having 1 to 4 carbons, an alkoxy group having 1 to 4 carbons, an alkylamino group having 1 to 4 carbons, an alkylamino group having 1 to 4 carbons, an acylamino group having 1 to 4 carbons, an acylamino group having 1 to 4 carbons, an alkylthio group having 1 to 4 carbons, a perfluoroalkyl group having 1 to 4 carbons, a perfluoroalkyloxy group having 1 to 4 carbons, a carboxyl group, an alkoxycarbonyl group having 1 to 4 carbons, a carboxyl group, an alkoxycarbonyl group having 1 to 4 carbons, a phenyl group and a heterocyclic group;

X is a bond or a moiety having a structure selected from those illustrated in formula (2):

wherein e is an integer of 1 to 4; g and m are independently an integer of 0 to 4; R⁴ is a hydrogen atom or an optionally substituted alkyl group having 1 to 4 carbons, or the acyl group represented by formula (3)

THAM

$$-$$
C $-$ R6 (3)

wherein R⁶ is an optionally substituted alkyl group having 1 to 4 carbons a perfluoroalkyl group having 1 to 4 carbons, a phenyl group or a heterocyclic group; R⁵ is a hydrogen atom or an optionally substituted alkyl group having 1 to 4 carbons;

n is an integer of 0 to 4, provided that when X is a bond, n is not zero;

Q is a moiety having a structure selected from those illustrated in formula (4)

wherein R^7 and R^8 are independently a hydrogen atom or an optionally substituted alkyl group having 1 to 4 carbons;

R¹ and R² are independently a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, an alkyl group having 1 to 4 carbons, an alkoxy group having 1 to 4 carbons, an aminoalkyl group having 1 to 4 carbons, an alkylamino group having 1 to 4 carbons, an acyl group having 1 to 4 carbons, an acyl group having 1 to 4 carbons, an acylamino group having 1 to


4 carbons, an alkylthio group having 1 to 4 carbons, a perfluoroalkyl group having 1 to 4 carbons, a perfluoroalkyloxy group having 1 to 4 carbons, a carboxyl group or an alkoxycarbonyl group having 1 to 4 carbons;

R³ is a hydroxyl or amino group X or a pharmaceutically acceptable salt thereof.

- 2. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 1, wherein n is an integer of 1 to 4.
- 3. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 2, wherein Q is selected from the structures illustrated in formula (5):

wherein ${\ensuremath{R}^{7}}$ and ${\ensuremath{R}^{8}}$ are as defined above.

- 4. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 3, wherein A is an optionally substituted hetero ring.
- 5. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 4, wherein A is an optionally substituted pyridyl group.
- 6. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 4, wherein X is a direct bond.
- 7. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 6, wherein ${\bf R}^1$ and ${\bf R}^2$ are a hydrogen atom.



9. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 5, wherein X is the structure represented by formula (6):

10. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 9, wherein n is 1; and \mathbb{R}^1 and \mathbb{R}^2 are a hydrogen atom.

11. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 10, wherein \mathbb{R}^3 is an amino group.

12. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 5, wherein X is selected from the structures illustrated in formula (7):

$$-(CH2)g-O-(CH2)e-$$
, $-(CH2)g-S-(CH2)e-$, (7)
R4
 $-(CH2)g-N-(CH2)e-$

Wherein e, g and R⁴ are as defined above.

acceptable salt thereof as claimed in Claim 12, wherein n is 1; and \mathbb{R}^1 and \mathbb{R}^2 are a hydrogen atom.

 $14\,.$ A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 13, wherein R^3 is an amino group.




15. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 5, wherein X is selected from the structures illustrated in formula (8):

 χ wherein g, m and R⁵ are as defined above.

- 16. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 15, wherein n is 1; and \mathbb{R}^1 and \mathbb{R}^2 are a hydrogen atom.
- 17. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 16, wherein \mathbb{R}^3 is an amino group.
- 18. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 1, wherein n is zero.
- 19. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 18, wherein Q is selected from the structures illustrated in formula (5).
- 20. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 19, wherein A is an optionally substituted hetero ring.
- 21. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 20, wherein A is an optionally substituted pyridyl group.



- 22. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 21, wherein ${\bf R}^1$ and ${\bf R}^2$ are a hydrogen atom.
- 23. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 22, wherein \mathbb{R}^3 is an amino group.
- 24. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 1 represented by formula (9) $_{\odot}$



25. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 1 represented by formula (10) \odot

26. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 1 represented by formula (11) \bigcirc

$$\begin{array}{c|c}
H & C \\
C & N \\
C & N
\end{array}$$

$$\begin{array}{c|c}
NH_2 \\
N \\
N
\end{array}$$

$$\begin{array}{c|c}
NH_2 \\
NH_2 \\
NH_2
\end{array}$$

$$\begin{array}{c|c}
NH_2 \\
NH_2$$

$$\begin{array}{c|c}
NH_2 \\
NH_2$$

$$\begin{array}{c|c}
NH_2 \\
NH_2
\end{array}$$

$$\begin{array}{c|c}
NH_2 \\
NH_2$$

$$\begin{array}{c|c}
NH_2 \\
NH_2
\end{array}$$

$$\begin{array}{c|c}
NH_2 \\
NH_2$$

$$\begin{array}{c|c}
NH_2 \\
NH_2
\end{array}$$

$$\begin{array}{c|c}
NH_2 \\
NH_2$$

$$\begin{array}{c|c}
NH_2 \\
NH_2
\end{array}$$

$$\begin{array}{c|c}
NH_2 \\
NH_2$$

$$\begin{array}{c|c}
NH_2 \\
NH_2
\end{array}$$

$$\begin{array}{c|c}
NH_2 \\
NH_2$$

$$\begin{array}{c|c}
NH_2 \\
NH_2
\end{array}$$

$$\begin{array}{c|c}
NH_2 \\
NH_2
\end{array}$$

$$\begin{array}{c|c}
NH_2 \\
NH_2$$

$$\begin{array}{c|c}
NH_2 \\
NH_2
\end{array}$$

$$\begin{array}{c|c}
NH_2 \\
NH_2$$

$$\begin{array}{c|c}
NH_2 \\
NH$$

27. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 1 represented by formula (12)

28. An anilide having the structure represented by formula (13):

And the train

[wherein A and B are independently an optionally substituted phenyl or heterocyclic group which has 1 to 4 substituents selected from the group consisting of a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, an alkyl group having 1 to 4 carbons, an alkoxy group having 1 to 4 carbons, an anino group having 1 to 4 carbons, an alkylamino group having 1 to 4 carbons, an acyl group having 1 to 4 carbons, an

acylamino group having 1 to 4 carbons, an alkylthio group having 1 to 4 carbons, a perfluoroalkyl group having 1 to 4 carbons, a perfluoroalkyloxy group having 1 to 4 carbons, a darboxyl group, an alkoxycarbonyl group having 1 to 4 carbons, a phenyl group and a heterocyclic group;

Y is a moiety having -CO-, -CS-, -SO- or $-SO_2-$ which is linear, cyclic or their combination and links A and B;

R³ is a hydroxy or amino group;

the distances between the centroid of ring B (W1), the centroid of ring A (W2) and oxygen or sulfur atom as a hydrogen bond acceptor in the moiety Y (W3) are as follows; W1-W2=6.0 to 11.0 Å, W1-W3=3.0 to 8.0 Å, and W2-W3=3.0 to 8.0 Å.] or a pharmaceutically acceptable salt thereof.

- 29. An anilide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 28, wherein A is an optionally substituted heterocycle; R³ is an amino group; and Y is a moiety having -CO- which is linear, cyclic or their combination and links A and B.
- 30. An anilide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 29, wherein B is an optionally substituted phenyl; W1-W2 is 7.0 to 9.5 Å; W1-W3 is 3.0 to 5.0 Å; and W2-W3 is 5.0 to 8.0
- 31. An anticancer drug comprising one or more compounds as claimed in any of Claims 1 to 30 as active

suba!

ingredients.

32. A pharmaceutical composition comprising one or more compounds as claimed in any of Claims 1 to 30 as active ingredients.

190